112 related articles for article (PubMed ID: 33600944)
1. A novel strategy for glioblastoma treatment by induction of noptosis, an NQO1-dependent necrosis.
Zhong B; Yu J; Hou Y; Ai N; Ge W; Lu JJ; Chen X
Free Radic Biol Med; 2021 Apr; 166():104-115. PubMed ID: 33600944
[TBL] [Abstract][Full Text] [Related]
2. 2-Methoxy-6-acetyl-7-methyljuglone (MAM) induced programmed necrosis in glioblastoma by targeting NAD(P)H: Quinone oxidoreductase 1 (NQO1).
Yu J; Zhong B; Jin L; Hou Y; Ai N; Ge W; Li L; Liu S; Lu JJ; Chen X
Free Radic Biol Med; 2020 May; 152():336-347. PubMed ID: 32234332
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma.
Lei K; Gu X; Alvarado AG; Du Y; Luo S; Ahn EH; Kang SS; Ji B; Liu X; Mao H; Fu H; Kornblum HI; Jin L; Li H; Ye K
J Hematol Oncol; 2020 Oct; 13(1):141. PubMed ID: 33087132
[TBL] [Abstract][Full Text] [Related]
4. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis.
Yu J; Zhong B; Zhao L; Hou Y; Ai N; Lu JJ; Ge W; Chen X
Drug Resist Updat; 2023 Sep; 70():100977. PubMed ID: 37321064
[TBL] [Abstract][Full Text] [Related]
5. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
6. NQO1 drives glioblastoma cell aggressiveness through EMT induction via the PI3K/Akt/mTOR/Snail pathway.
Zheng L; Yang S; Xu R; Yang Y; Quan J; Lin Z; Quan C
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594082
[TBL] [Abstract][Full Text] [Related]
7. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
8. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis.
Ahn KS; Sethi G; Jain AK; Jaiswal AK; Aggarwal BB
J Biol Chem; 2006 Jul; 281(29):19798-808. PubMed ID: 16682409
[TBL] [Abstract][Full Text] [Related]
9. NQO1 Is Regulated by PTEN in Glioblastoma, Mediating Cell Proliferation and Oxidative Stress.
Luo S; Lei K; Xiang D; Ye K
Oxid Med Cell Longev; 2018; 2018():9146528. PubMed ID: 30595797
[TBL] [Abstract][Full Text] [Related]
10. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
11. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
13. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
Tudor G; Alley M; Nelson CM; Huang R; Covell DG; Gutierrez P; Sausville EA
Anticancer Drugs; 2005 Apr; 16(4):381-91. PubMed ID: 15746574
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of NAD(P)H: Quinone Oxidoreductase 1 Inhibits Hepatocellular Carcinoma Cell Proliferation and Induced Apoptosis by Activating AMPK/PGC-1α Pathway.
Zhang X; Han K; Yuan DH; Meng CY
DNA Cell Biol; 2017 Apr; 36(4):256-263. PubMed ID: 28191864
[TBL] [Abstract][Full Text] [Related]
18. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
19. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
20. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
